Thursday, 25 Apr 2019

You are here

Diet and Weight Loss Improves Psoriatic Arthritis

Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin. 

Obesity is highly prevalent in psoriatic patients and is associated with higher disease activity, poorer effect of treatment and increased cardiovascular morbidity. 

VLED (640 kcal/day) was taken during 12–16 weeks, depending on pre-treatment BMI. Afterwards, an energy-restricted diet was gradually reintroduced. 

A total of 46 patients were enrolled and maintained on static treatment with conventional and/or biologic disease-modifying anti-rheumatic drugs from 3 months before, until 6 months after, baseline. 

A total 46 patients were enrolled and 41 completed the study; increased BMI at baseline was associated with higher disease activity and poorer function.

The median weight loss in the trial was 18.7 kg (IQR 14.6–26.5) or 18.6% of the baseline weight.

Disease parameters improved significantly after weight loss, including tender/swollen joint counts, CRP, BSA, Leeds enthesitis index, HAQ and patient VAS for global health, pain and fatigue.

Weight loss was associated with an increase in minimal disease activity (MDA) from 29 to 54%, (p = 0.002).

ACR 20, 50 and 70 responses were 51.2%, 34.1% and 7.3% respectively, at 6 months follow-up. A larger weight loss resulted in more improvement in a dose-response manner. The treatment was effective, safe and well tolerated.

These findings were underscored by recent dietary recommendations from the National Psoriasis Foundation.(Citation https://buff.ly/2Noqidk and  https://buff.ly/2CfRkyw)

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Skyrizi (risankizumab) FDA Approved for Psoriasis

AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis. 

Skyrizi is an interleukin-23 (IL-23) inhibitor that was also recently approved in Canada and Japan. Skyrizi is the third IL-23 inhibitor (behind guselkumab [Tremfya] and tildrakizumab [Ilumya]) to be approved in the last year.

Higher Comorbidities in Hidradenitis Suppurativa

JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.

A cross-sectional study compared 5306 HS patients, 14 037 patients with psoriasis, and 1 733 810 controls from electronic health records between 2013 and 2018. Specifically they examined comorbidities using the Charlson Comorbidity Index (CCI) score.

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

Dual IL-17 Inhibitor in Psoriasis Succeeds

Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed. 

AAD/NPF Guidelines on Biologic Use in Psoriasis

Menter and colleagues from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) have published their expert consensus guidelines for the use of biologics in psoriasis.